NCT02177682View on ClinicalTrials.gov

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 13, 2014

Primary Completion Date

February 9, 2017

Study Completion Date

August 14, 2019

Conditions
Neoplasms, Haematologic
Interventions
DRUG

Afuresertib

Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.

Trial Locations (5)

467-8602

Novartis Investigative Site, Aichi

811-1395

Novartis Investigative Site, Fukuoka

980-8574

Novartis Investigative Site, Miyagi

951-8566

Novartis Investigative Site, Niigata

104-0045

Novartis Investigative Site, Tokyo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY